An interim analysis of the HARMONI-2 trial indicates that the investigational drug Ivonescimab shows a 22% reduction in the risk of death compared to pembrolizumab for patients with PD-L1 positive progressive non-small cell lung cancer (NSCLC). Conducted in China, this Phase III trial reported a hazard ratio of 0.777 based on 39% data maturity. Ivonescimab has been approved for use in frontline therapy for NSCLC by China’s National Medical Products Administration (NMPA).
The trial evaluated Ivonescimab monotherapy against pembrolizumab’s monotherapy in patients with locally advanced or metastatic NSCLC. Akeso, the sponsor, stated that the results demonstrated a significant improvement in overall survival, leading to optimism about Ivonescimab’s potential as a next-generation PD-1 immunotherapy.
The company is also enrolling patients in the HARMONI-7 trial, comparing Ivonescimab to pembrolizumab in various settings. Ivonescimab is designed with unique binding properties to enhance efficacy, especially in cancer tissues.
Summit Therapeutics is focusing on the commercialization of Ivonescimab and has numerous ongoing clinical trials worldwide, with the treatment recently gaining fast-track designation from the FDA.
Source link
